Business Context and Reporting Period
Company: CARLSMED, INC. (CARL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Carlsmed is a medical technology company developing AI-enabled personalized spine surgery solutions via the aprevo Technology Platform. The platform includes proprietary surgical planning software and patient-specific implants for lumbar and cervical spine fusion. The company completed its IPO in July 2025 and is classified as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $16,116 | $10,189 |
| Gross Profit | $12,425 | $7,636 |
| Gross Margin | 77.1% | 74.9% |
| Net Loss | $(8,696) | $(5,729) |
| Operating Cash Flow | $(13,007) | $(8,155) |
| Cash & Equivalents (End of Period) | $73,016 | $43,432 |
| Total Debt Outstanding | $15,364 | N/A |
Note: Debt figures represent the long-term portion of the term loan, net of issuance costs. Total principal outstanding is $15.6 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 58.2% year-over-year to $16.1 million, driven by higher surgical procedure volumes. Average revenue per procedure remained substantially constant.
- Expense Expansion: Total operating expenses rose 62.5% to $21.7 million.
- R&D: Increased 64.4% to $5.2 million due to higher personnel costs for AI and product development.
- Sales & Marketing: Increased 52.8% to $10.3 million, driven by headcount growth, sales commissions, and marketing initiatives.
- G&A: Increased 79.6% to $6.2 million, reflecting public company compliance costs and professional fees.
- Profitability: Net loss widened to $8.7 million from $5.7 million due to accelerated operating spend outpacing revenue growth.
- Liquidity: Cash and cash equivalents decreased by approximately $12.8 million during the quarter due to operating cash burn, despite interest income of $0.9 million.
Outlook, Risks, and Management Commentary
- Product Launches: The company commercially launched the aprevo Cervical platform in December 2025. The corra Cervical Plating System is expected to launch commercially by December 2026, and aprevo bi-lateral is planned for Q4 2026.
- Reimbursement: CMS adopted new MS-DRG coding for lumbar procedures in October 2024, providing additional reimbursement. A FY2027 proposal released in April 2026 suggests further validation of the platform's value. The company is pursuing Transitional Pass-Through (TPT) payments for outpatient cervical procedures.
- Liquidity Position: Management believes existing cash ($97.1 million including short-term investments) and available credit ($26.9 million remaining on the term loan) are sufficient to fund operations for at least 12 months.
- Risks: Key risks include reliance on third-party contract manufacturers, the need for continued regulatory approvals, reimbursement rate changes, and the ability to attract and retain surgeon users. The company maintains a full valuation allowance on deferred tax assets.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the ~$13 million quarterly operating cash burn against the $97 million cash runway.
- Reimbursement Finalization: Monitor the finalization of the CMS FY2027 IPPS rule regarding new MS-DRG codes for lumbar procedures.
- Debt Covenants: Review the Customers Loan Agreement milestones, specifically the revenue targets required to extend the interest-only period and access additional tranches.
- Product Adoption: Track the adoption rate of the newly launched cervical and bi-lateral products to ensure they drive the projected revenue growth.
- Stock-Based Compensation: Assess the impact of the $1.6 million quarterly stock-based compensation expense on future dilution and cash flow.